Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2014, Article ID 595132, 10 pages
http://dx.doi.org/10.1155/2014/595132
Research Article

A Delphi Study to Detect Deficiencies and Propose Actions in Real Life Treatment of Neovascular Age-Related Macular Degeneration

1Clínica Universidad de Navarra, Avenida de Pío XII 36, 31008 Pamplona, Spain
2Hospital de Bellvitge, C/Feixa Llargasn, L’Hospitalet de Llobregat, 08907 Barcelona, Spain
3Hospital Universitario Ramon y Cajal, Carretera de Colmenar km 9, 28034 Madrid, Spain
4Vissum Madrid, Santa Hortensia 58, 28002 Madrid, Spain
5Hospital de San Eloy, Avenida Antonio Miranda 5, 48902 Baracaldo, Spain
6Hospital Universitario de Albacete, Avenida de Almansa, s/n, 02006 Albacete, Spain
7Hospital VallD’Hebron, Passeig de la Valld’Hebron 119-129, 08035 Barcelona, Spain
8Instituto Oftalmológico Gómez-Ulla, Calle Maruja Mallo 3, 15706 Santiago de Compostela, Spain
9IOBA, Hospital Clínico Universitario de Valladolid, Paseo de Belén 17, 47011 Valladolid, Spain
10Complejo Hospitalario Universitario Insular Materno Infantil de Gran Canaria, Avenida Marítima del Sur, s/n, 35016 Las Palmas de Gran Canaria, Spain
11Hospital Universitario Virgen de la Victoria, Campus de Teatinos, s/n, 29010 Málaga, Spain
12Institut de la Macula i de la Retina, Carrer de Vilana 12, 08022 Barcelona, Spain
13Hospital General de Valencia, Avenida Tres Cruces 2, 46014 Valencia, Spain
14Hospital la Paz, Paseo de la Castellana 261, 28046 Madrid, Spain
15Hospital la Fe, Valencia, Avenida de Fernando Abril Martorell 106, 46026 Valencia, Spain
16Hospital Universitario de Valme, Avenida de Bellavista, s/n, 41014 Sevilla, Spain
17Hospital Universitario Nuestra Señora de la Candelaria, Carretera del Rosario 145, 38010 Santa Cruz de Tenerife, Spain

Received 13 October 2014; Accepted 7 November 2014; Published 21 December 2014

Academic Editor: Siamak Ansari-Shahrezaei

Copyright © 2014 Alfredo García-Layana et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Soubrane, A. Cruess, A. Lotery et al., “Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study,” Archives of Ophthalmology, vol. 125, no. 9, pp. 1249–1254, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. P. J. Rosenfeld, D. M. Brown, J. S. Heier et al., “Ranibizumab for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 355, no. 14, pp. 1419–1431, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. U. Schmidt-Erfurth, P. K. Kaiser, J.-F. Korobelnik et al., “Intravitreal aflibercept injection for neovascular age-related macular degeneration: Ninety-six-week results of the VIEW studies,” Ophthalmology, vol. 121, no. 1, pp. 193–201, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. G. A. Lalwani, P. J. Rosenfeld, A. E. Fung et al., “A variable-dosing regimen with intravitrealranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study,” The American Journal of Ophthalmology, vol. 148, no. 1, pp. 43.e1–58.e1, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. D. F. Martin, M. G. Maguire, G.-S. Ying, J. E. Grunwald, S. L. Fine, and G. J. Jaffe, “Ranibizumab and bevacizumab for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 364, no. 20, pp. 1897–1908, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. B. G. Busbee, A. C. Ho, D. M. Brown et al., “Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration,” Ophthalmology, vol. 120, no. 5, pp. 1046–1056, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. L. J. Hernandez-Pastor, A. Ortega, A. García-Layana, and J. Giráldez, “Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 248, no. 4, pp. 467–476, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Krüger Falk, H. Kemp, and T. L. Sorensen, “Four-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment,” American Journal of Ophthalmology, vol. 155, no. 1, pp. 89–95, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. M. A. Singer, C. C. Awh, S. Sadda et al., “HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration,” Ophthalmology, vol. 119, no. 6, pp. 1175–1183, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. Tano, M. Ohji, and EXTEND-I Study Group, “Long-term efficacy and safety of ranibizumab administered pro re nata in Japanese patients with neovascular age-related macular degeneration in the EXTEND-I study,” Acta Ophthalmologica Scandinavica, vol. 89, no. 3, pp. 208–217, 2011. View at Publisher · View at Google Scholar
  11. G. Querques, S. Azrya, D. Martinelli et al., “Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting,” British Journal of Ophthalmology, vol. 94, no. 3, pp. 292–296, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Biarnés, J. Monés, J. R. Villalbí, and L. Arias, “As-needed treatment with ranibizumab 0.5 mg in patients with neovascular age-related macular degeneration,” European Journal of Ophthalmology, vol. 21, no. 3, pp. 282–289, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. N. M. Lees and J. J. Lievaart, “Expert opinion on ranking risk factors for subclinical mastitis using a modified Delphi technique,” New Zealand Veterinary Journal, vol. 61, no. 3, pp. 168–173, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Hasson, S. Keeney, and H. McKenna, “Research guidelines for the Delphi survey technique,” Journal of Advanced Nursing, vol. 32, no. 4, pp. 1008–1015, 2000. View at Google Scholar · View at Scopus
  15. S. Keeney, F. Hasson, and H. McKenna, “Consulting the oracle: ten lessons from using the Delphi technique in nursing research,” Journal of Advanced Nursing, vol. 53, no. 2, pp. 205–212, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. M. G. Tolsgaard, T. Todsen, J. L. Sorensen et al., “International multispecialty consensus on how to evaluate ultrasound competence: a Delphi consensus survey,” PLoS ONE, vol. 8, no. 2, Article ID e57687, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. J. M. Ruiz-Moreno, L. Arias-Barquet, F. Armadá-Maresca et al., “Guidelines of clinical practice of the SERV: treatment of exudative age-related macular degeneration (AMD),” Archivos de la Sociedad Española de Oftalmología, vol. 84, no. 7, pp. 333–344, 2009. View at Google Scholar · View at Scopus
  18. A. Fink, J. Kosecoff, M. Chassin, and R. H. Brook, “Consensus methods: characteristics and guidelines for use,” The American Journal of Public Health, vol. 74, no. 9, pp. 979–983, 1984. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Singh, R. Aggarwal, B. Zevin, T. Grantcharov, and A. Darzi, “A global Delphi consensus study on defining and measuring quality in surgical training,” Journal of The American College of Surgeons, vol. 219, no. 3, pp. 346–353, 2014. View at Google Scholar
  20. B. Zevin, E. M. Bonrath, R. Aggarwal, N. J. Dedy, N. Ahmed, and T. P. Grantcharov, “Development, feasibility, validity, and reliability of a scale for objective assessment of operative performance in laparoscopic gastric bypass surgery,” Journal of the American College of Surgeons, vol. 216, no. 5, pp. 955.e8–965.e8, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Nagpal, S. Arora, M. Abboudi et al., “Postoperative handover: problems, pitfalls, and prevention of error,” Annals of Surgery, vol. 252, no. 1, pp. 171–176, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Mitchell, J.-F. Korobelnik, P. Lanzetta et al., “Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials,” British Journal of Ophthalmology, vol. 94, no. 1, pp. 2–13, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. R. Casaroli-Marano and M. Roura, “Availability of resources for patients with wet age-related macular degeneration. Optimal study,” Archivos de la Sociedad Española de Oftalmología, vol. 88, no. 8, pp. 307–312, 2013. View at Publisher · View at Google Scholar
  24. G. Menon, M. Chandran, S. Sivaprasad, R. Chavan, N. Narendran, and Y. Yang, “Is it necessary to use three mandatory loading doses when commencing therapy for neovascular age-related macular degeneration using bevacizumab? (BeMOc Trial),” Eye (Basingstoke), vol. 27, no. 8, pp. 959–963, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. R. F. Spaide, “The as-needed treatment strategy for choroidal neovascularization: a feedback-based treatment system,” American Journal of Ophthalmology, vol. 148, no. 1, pp. 1–3, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. N. Toalster, M. Russell, and P. Ng, “A 12-month prospective trial of inject and extend regimen for ranibizumab treatment of age-related macular degeneration,” Retina, vol. 33, no. 7, pp. 1351–1358, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Oubraham, S. Y. Cohen, S. Samimi et al., “Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration,” Retina, vol. 31, no. 1, pp. 26–30, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Arias, I. Roman, C. Masuet-Aumatell et al., “One-year results of a flexible regimen with ranibizumab therapy in macular degeneration: relationship with the number of injections,” Retina, vol. 31, no. 7, pp. 1261–1267, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Y. Cohen, L. Dubois, R. Tadayoni et al., “Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting,” American Journal of Ophthalmology, vol. 148, no. 3, pp. 409–413, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Casparis, T. J. Wolfensberger, M. Becker et al., “Incidence of presumed endophthalmitis after intravitreal injection performed in the operating room: a retrospective multicenter study,” Retina, vol. 34, no. 1, pp. 12–17, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. F. Gómez-Ulla, E. Basauri, L. Arias, and F. Martínez-Sanz, “Management of intravitreal injections,” Archivos de la Sociedad Espanola de Oftalmologia, vol. 84, no. 8, pp. 377–388, 2009. View at Google Scholar · View at Scopus
  32. A. N. Stangos, J. S. Gandhi, J. Nair-Sahni, H. Heimann, C. J. Pournaras, and S. P. Harding, “Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab,” American Journal of Ophthalmology, vol. 150, no. 5, pp. 666–673, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Talks, Z. Koshy, and K. Chatzinikolas, “Use of optical coherence tomography, fluorescein angiography and indocyanine green angiography in a screening clinic for wet age-related macular degeneration,” The British Journal of Ophthalmology, vol. 91, no. 5, pp. 600–601, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Tozer, A. B. Roller, L. P. Chong et al., “Combination therapy for neovascular age-related macular degeneration refractory to anti-vascular endothelial growth factor agents,” Ophthalmology, vol. 120, no. 10, pp. 2029–2034, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. V. Y. Ho, S. Yeh, T. W. Olsen et al., “Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors,” American Journal of Ophthalmology, vol. 156, no. 1, pp. 23.e2–28.e2, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. I. Krebs, C. Glittenberg, S. Ansari-Shahrezaei, S. Hagen, I. Steiner, and S. Binder, “Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration,” British Journal of Ophthalmology, vol. 97, no. 11, pp. 1443–1446, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Rofagha, R. B. Bhisitkul, D. S. Boyer, S. R. Sadda, and K. Zhang, “Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP),” Ophthalmology, vol. 120, no. 11, pp. 2292–2299, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. W. Amoaku, “Ranibizumab: the clinician's guide to commencing, continuing, and discontinuing treatment,” Eye, vol. 25, no. 4, pp. 663–675, 2011. View at Google Scholar
  39. A. Gaudric and S. Y. Cohen, “When should anti-vascular endothelial growth factor treatment be stopped in age-related macular degeneration?” American Journal of Ophthalmology, vol. 149, no. 1, pp. 4–6, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. P. A. Keane, A. Tufail, and P. J. Patel, “Management of neovascular age-related macular degeneration in clinical practice: initiation, maintenance, and discontinuation of therapy,” Journal of Ophthalmology, vol. 2011, Article ID 752543, 10 pages, 2011. View at Publisher · View at Google Scholar